Medical condition
Sickle Cell
Sickle Cell is a medical condition tracked by NovaPharmaNews across 5 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- exagamglogene autotemcel (CASGEVY) Blood and blood forming organs (B06)
- voxelotor (OXBRYTA) Blood and blood forming organs (B06)
- sulesomab (LEUKOSCAN) Various (VO4)
- crizanlizumab (ADAKVEO) Blood and blood forming organs (B06)
- hydroxycarbamide (HYDREA) Antineoplastic and immunomodulating agents (L01)
Latest Sickle Cell news
FDA Concerns About Cancer Risk Sink Fulcrum Therapeutics’ Sickle Cell Disease Drug: Implications for SCD Pipeline and BD Strategy
Fulcrum Therapeutics is discontinuing its lead sickle cell disease drug, pociredir, after the FDA raised concerns about cancer risk. The decision, which sent shares down 52%, reshapes the SCD competitive landscape and opens strategic questions for pipeline watchers and BD teams.
Fulcrum Therapeutics Stock Plummets 54% Following Sickle Cell Drug Discontinuation
Fulcrum Therapeutics' stock experienced a significant 54% drop following the discontinuation of its sickle cell disease drug, citing regulatory hurdles. This event highlights potential challenges in clinical trial design for the indication.
Fulcrum Explores Sale Amid FDA Setback for Sickle Cell Drug
Fulcrum Therapeutics is reportedly exploring strategic alternatives, including a potential sale, after the FDA raised concerns about its lead sickle cell drug, pociredir. This move follows similar market withdrawals for other sickle cell treatments.
FDA Approves First CRISPR Gene Therapy for Sickle Cell Disease
The FDA has approved Zynteglo, the first CRISPR gene therapy for sickle cell disease, offering new hope for patients with this debilitating condition.